BIOMAKERS Secures $8.0

BIOMAKERS, a global Precision Medicine Company, has secured $8.0 million in a recent funding round from investors.

This capital infusion is set to bolster the company's mission to advance cancer patient longevity and transform oncology data-driven drug development globally.

BIOMAKERS specializes in producing complex and advanced genomic data alongside Real-World Evidence (RWE) to support its comprehensive approach to precision medicine.

The company has developed an advanced platform that facilitates diagnosis, treatment, drug development, target discovery, and AI applications for both cancer and rare diseases.

BIOMAKERS offers genomic products across all four stages of the biopharmaceutical chain and provides extensive genomic and molecular testing services to patients in over 18 countries across Latin America.

Its efforts are particularly significant for offering the largest Latin American genomic representation within the global oncology drug development landscape.

In a relatively short period, BIOMAKERS has established itself as a leading entity in Precision Medicine within the region.

It has built a unique multinational Advanced Tumor Biobank and Cancer Dataset sourced from Latin America, with its headquarters in the USA and fully owned sequencing laboratories located in Mexico, Brazil, and Argentina.

The newly raised funds will be strategically deployed to accelerate the company's growth initiatives, expand its operational footprint, and further enhance its proprietary technology platform.

This investment round highlights investor confidence in BIOMAKERS' innovative model and its capacity to drive significant advancements in precision oncology.

Looking ahead, the company plans to continue expanding its reach and impact, aiming to make precision medicine more accessible and effective for patients worldwide, while further solidifying its position as a pivotal provider of genomic data for cancer and rare diseases.